Stock 6628 TRANSCENTA HOLDING LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Transcenta Holding Limited

Equities

6628

KYG9005B1041

Delayed Hong Kong S.E.
Other stock markets
 02:51:06 07/05/2024 BST 		5-day change 1st Jan Change
1.88 HKD 0.00% Intraday chart for Transcenta Holding Limited +3.87% -47.63%
04-30 Transcenta Holding Limited Announces Board and Nomination Changes CI
04-09 Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 5.93 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TRANSCENTA HOLDING LIMITED Stock Transcenta Holding Limited
-47.63% 94.18M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.52% 662B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.96% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.21% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.02% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.01% 289B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.81% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.63% 194B
A+
AMGEN INC. Stock Amgen Inc.
+3.98% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6628 Stock
  4. Ratings Transcenta Holding Limited